iKala's Traditional Chinese Validation Set "TMMLU+" Gains Top AI Conference Endorsement, Showcasing iKala's Expertise

TAIPEI, Aug. 14, 2024 /PRNewswire/ -- As AI technology continues its rapid advancement, the demand for traditional Chinese models in the Taiwanese market is increasing. In response to this need, iKala, a leading AI transformation solutions provider, has unveiled its new traditional Chinese validation set, "TMMLU+." This innovative tool has been officially featured in the inaugural issue of the prestigious Conference on Language Modeling (COLM).

The conference was founded by renowned experts from DeepMind, Meta, Microsoft, and Ivy League institutions, is a highly respected authority in the field of AI. The TMMLU+ validation set achieved a top 10% score during the review process of numerous papers, highlighting iKala's terrific expertise in AI technology.

iKala Launches TMMLU+ Validation Set to Enhance Accuracy and Localization of Traditional Chinese LLMs

The launch of TMMLU+ validation set is poised to significantly boost the accuracy and localization of large language models for traditional Chinese. With the rise of generative AI, nations worldwide are focusing on developing language models that cater to their specific linguistic needs. In Taiwan, several companies are working on creating traditional Chinese AI models. Given the linguistic and cultural nuances unique to Taiwan, such as terms like "8+9," "Beicheng," and local Taiwanese dialects, specialized validation sets are essential for fine tuning these models to achieve precise and relevant AI applications.

iKala's AI team has leveraged the TMMLU framework from MediaTek and expanded it using social media data to encompass a broader array of Taiwanese local usage and cultural references. This enhancement allows the TMMLU+ validation set to better reflect the linguistic context and expressions specific to traditional Chinese. The open source TMMLU+ validation set is designed to support local enterprises in validating their traditional Chinese language models, ensuring they will be fine tuned to meet the needs.

iKala Traditional Chinese Validation Set TMMLU+ Stands Out Globally,

On October 23, the AI team began to develop TMMLU+ validation set which underwent intensive work over several months. It had been submitted to COLM for review in the spring of 2024. During the process of review, iKala's AI team provided a comprehensive explanation of the unique characteristics in traditional Chinese and the value of TMMLU+. This presentation significantly impressed the reviewers and effectively enhanced the TMMLU+ validation set's paper rating, allowing it to stand out from global competitors.

The TMMLU+ validation set has already been adopted by several Taiwanese companies for evaluating large language models, establishing a reliable and standardized benchmark for the tech industry in Taiwan. This recognition not only affirms iKala's years of dedication to advancing AI technology but also enhances its influence and authority in the industry.

iKala Co-founder and CEO Sega Cheng commented, "As a multinational AI company based in Taiwan, iKala is dedicated to solving complex and meaningful AI challenges, with a focus on delivering business value and practical applications. We are extremely grateful for the efforts of our AI team for their hard work, which has allowed us to gain international recognition. We also extend our thanks to MediaTek for leading the way in Taiwan's AI open source technology."

ã€About iKala】

iKala is a leading AI transformation solutions provider, with a mission to "enable AI competencies" of enterprises by providing AI-driven cloud management and MarTech solutions, to optimize their operational efficiency and increase customer engagement. iKala's solutions and SaaS products are available in 7 countries, enabling over 1,000 enterprises and top-tier brands, including Fortune 500 companies, to transform their business.

iKala Official Website: https://ikala.ai/zh-tw/

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

iKala's Traditional Chinese Validation Set "TMMLU+" Gains Top AI Conference Endorsement, Showcasing iKala's Expertise

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.

Biosyngen, an innovative biotechnology company specializing in immune cell therapies, has showcased its groundbreaking technology on gene-modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer biopsy samples.

BioSyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year.

Abstract Title

Pre-clinical Development of Genetically Modified Tumor-infiltrating Lymphocytes using Biopsy Samples from Liver Cancer Patients

Abstract No.

1034P

Tumor-infiltrating lymphocytes (TILs) are heterogeneous lymphocyte populations within the tumor microenvironment that contains T cells capable of recognizing tumor- or virus-associated antigens. In February of this year, the FDA approved the first TIL-based therapy used with IL-2 for advanced metastatic/recurrent melanoma. However, due to the variability in T cell infiltration between hot and cold tumors, differential abundance of antigen-specific T cells with robust immune response functionality, and the dependence of TIL anti-tumor efficacy on concomitant use of high-dose IL-2 combination therapy, the therapeutic applications of non-edited TILs are quite limited outside of melanoma.

To address these challenges, Biosyngen has developed a proprietary platform for expanding TILs from biopsy samples, achieving production of 10¹¹ cells within four weeks. Additionally, the company has established a stable gene modification platform that reprograms TIL metabolism, enhances TIL activity and sustained antitumor efficacy by expressing membrane anchor proteins. Anti-tumor efficacy has significantly enhanced (without IL-2 co-injection) and no obvious toxicity observed.

Biosyngen houses best-in-class proprietary TIL platform aiming to expand the clinical applications of TIL technology with following features:

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting